I appreciate this @jama.com commentary by Knox and @asarpatwari.bsky.social. I'm among the skeptics of the 340B program as it currently operates, but it appears this proposed pilot would not address the major issues. jamanetwork.com/journals/jam...

Presenting our new study at #ASCO26 right now! Provider profits on cancer drugs have grown 4-fold to $40 billion in the last decade and a half. @ascocancer.bsky.social @mskcancercenter.bsky.social @hannahrabrams.bsky.social @nihcm.bsky.social

Presenting at #ASCO26 now! Our new study: Bribes from the drug industry can lead oncologists to use WORSE treatments (not just better ones) @ascocancer.bsky.social @mskcancercenter.bsky.social @dusetzinas.bsky.social @commonwealthfund.org @nihcm.bsky.social @arnoldventures.bsky.social

New RCT evidence from @adrianna.bsky.social and coauthors testing effects of work requirements for SNAP Some enrollees get exemptions, others did not Work requirements had very small effects on employment, but large effects on enrollment Preview of what to expect in Medicaid next year #ARM26

Farewell #ARM26! #ASCO26, see you in about 5 hours! @ascocancer.bsky.social @academyhealth.bsky.social

Hey, #ARM2026 attendees. Sorry I can't be with you in Seattle. Fellow some of these great health systems and health policy researchers and those in the know. If you want me to add you, feel free to comment here and I can. #hpss #hspr #hpsr #healthpolicy

I'll be presenting new findings at 2:15 PT today at #ARM26! Our study measured provider profits on cancer drugs (profits have increased, a lot) This looks like a great session, including other new findings on cancer care in MA. See you in ballroom 6C! academyhealth.confex.com/academyhealt...

Excited to present preliminary results from a project that has been ongoing ~since I was a PhD student~ at today's late-breaking #ARM26 session — join us at 4p PT in rooms 613-614.

The webinar recording is now available, below. I'm also looking forward to presenting these findings on Medicare Advantage and cancer care at @academyhealth.bsky.social #ARM26, this weekend! cbiit.webex.com/recordingser...

Here’s how he blew off 19 kids killed by Covid in 1 month.

Next week at #ASCO26 @ascocancer.bsky.social I'll be presenting new evidence that industry COI influences which treatments oncologists prescribe...even for the non-so-good ones! www.asco.org/abstracts-pr...

Looking forward to presenting our new study at the @ascocancer.bsky.social annual meeting! We measured the recent, large increase in provider profits on cancer drugs: www.asco.org/abstracts-pr... @dusetzinas.bsky.social @sangerkatz.bsky.social @kffhealthnews.org @dylanlscott.bsky.social

Fixed it

confirmed here by multiple sources!! another fun rumor is apparently the small and inexperienced firm taking over will subcontract the work back to ResDAC! I can feel the efficiency growing!

Bhattacharya’s legacy The US had a “world-class Ebola lab in Frederick, Maryland, with the NIH,” designed to develop vaccines & treatments. The lab would normally be swinging into action. “But that lab was shuttered last year, with staff laid off abruptly”😢 www.theguardian.com/world/2026/m...

My recent personal experience with this topic du jour: when my name appeared in a non-existent LLM-generated citation bsky.app/profile/thew...

I'll be presenting some of our recent work on Medicare Advantage and its impacts on cancer care cost and quality, 3pm EST TODAY! Part of ongoing NCI seminar series. Webinar registration at the link below: healthcaredelivery.cancer.gov/media/medica...

It’s easy to forget how little oncology in the academic medical centers reflects what most patients experience. Across the whole system, only half of patients with lung cancer receive any treatment at all. jamanetwork.com/journals/jam...

Kinda burying the lead here, NPR

“A neurosurgery practice outside of Philadelphia went to arbitration after the health plan Highmark offered its standard payment of $2,660 for a diagnostic procedure to measure blood flow to the brain. An arbitrator awarded it $333,000 instead.” www.nytimes.com/2026/04/22/u... @nytimes.com

“A neurosurgery practice outside of Philadelphia went to arbitration after the health plan Highmark offered its standard payment of $2,660 for a diagnostic procedure to measure blood flow to the brain. An arbitrator awarded it $333,000 instead.” www.nytimes.com/2026/04/22/u... @nytimes.com

Accelerated approval makes sense in concept, but is failing in practice. It results in many drugs - especially cancer drugs - reaping huge profits for manufacturers despite proof of benefit for patients. Here’s how to fix it 👇🏼👇🏼👇🏼

New @icer-review.bsky.social whitepaper on FDA Accelerated Approval. This pathway is good in theory, and a failure in practice. Here's how to fix it! icer.org/news-insight... @yalecrrit.bsky.social @jsross119.bsky.social

Story in @nature.com about this exact problem: www.nature.com/articles/d41...

Revlimid has its origin in a pill that cost patients $7.50 each. Decades later, the cancer drug costs more than $18,000 for a month’s supply — even though it still only costs about 25 cents to manufacture. (Published May 2025)

“My patient is refusing a drug studied in 170,000 people because of side effects that a 124,000-person analysis just confirmed do not exist — while injecting a compound studied in 14 humans, from unregulated sources, based on the recommendation of someone who profits from selling it.”

New report on the impacts of a PhRMA push to delay the time before a drug's price could be negotiated in Medicare: www.citizen.org/article/epic...

Google's AI confusing the CDMRP with the NIH, and giving flatly wrong information on grant applications. (the CDMRP does not allow resubmissions)

Our latest, out today in JCNI: Is private equity ownership associated with increased use of low-value but lucrative cancer care services? Surprisingly, our answer seems to be “no” pubmed.ncbi.nlm.nih.gov/41912420/

In case you’re wondering who is getting rich from GOP decision to purge millions from Medicaid: kffhealthnews.org/news/article...

Impressive ROI on bribes from robot manufacturers to get doctors to use robot-assisted surgery! New study in @jamanetworkopen.com

Today, MSF is going public with something we've been fighting behind closed doors for months: Gilead will not sell us their new HIV drug, lenacapavir. The sticking point isn't even price, they just refuse to sell. Open letter linked + explainer 🧵1/ www.doctorswithoutborders.org/latest/gilea...

"doctors just give you pills, I only take dozens of wellness pills instead"

Pet peeve: un-self-aware academic junket culture. We spend $2000 to attend conferences where 75% of speakers rail against American inequality, while we splurge on $75 dinners, stay in $300/night hotel rooms, and take a $50 uber ride to avoid a 3-stop subway ride that would cost $2.50.

Remarkable retraction notice.

Update: This paper has now been retracted. cc @stevejoffe.bsky.social

This is an incredible documentation of the systematic, intentional collapse of American health science, by Elizabeth Ginexi. open.substack.com/pub/elizabet...

"This cross-sectional study found that pharmaceutical manufacturers penalized for kickbacks paid only 2.2% of US revenue accrued from selling implicated drugs during years of alleged violations." Great work by Tobias Liu @jsross119.bsky.social @reshmagar.bsky.social jamanetwork.com/journals/jam...

New @jama.com commentary by @rachelsachs.bsky.social @dusetzinas.bsky.social &myself on biosimilar drug competition and price declines. jamanetwork.com/journals/jam...

"Among...prescribers of PAH therapies, drug‐specific industry payments were associated with dose‐response increases in Medicare spending." New study to add to the list - industry payments affect physician prescribing pubmed.ncbi.nlm.nih.gov/41804477/

No one should care about Vinay Prasad’s opinions on anything ever again. There’s no reason at all to invite him on podcasts or invite him to write an article. He spread COVID disinformation, enabled MAHA, and turned the FDA in a soap opera. That’s all that matters.

The data is in: the NIH goalposts have shifted. What were once almost certain fundable scores have become coin flips and what used to be likely grants have become aspirational, leading to fewer awards. Another manifestation of how HHS policies have led to fewer awards and less science.

"Faculty at every school accepted industry payments, including 20 (16.7%) deans and 52 (19.3%) of clerkship directors." Update on COI at US medical schools, out in @plosone.org from Shamik Bhat, @timandersonmd.bsky.social &co pubmed.ncbi.nlm.nih.gov/41790718/

“Nobody wants that product,” said Amitabh Chandra, a Harvard health economist who has studied high-deductible plans. Gift link www.nytimes.com/2026/02/26/h...

The flu and pneumonia kill over 45,000 people a year. Moderna developed a new mRNA flu vaccine for people 50 and older--who are most at risk. Prasad, unilaterally, against the recommendation of experts within the agency, denied Moderna's appplication. www.statnews.com/2026/02/11/m...

🚨🚨🚨 Since we need all the good news we can get these days! CMS reverses plan to end physical data requests and transition all researchers to the VRDC platform: resdac.org/cms-news/res... cc @basucally.bsky.social @aschwartz.bsky.social @academyhealth.bsky.social @wschpero.bsky.social

It is really, really sad and angering when one of your own switches sides and joins Team Disease full-on

Honored to be among this year's cohort of grant awardees from the @nihcm.bsky.social ! Drs. Aaron Winn, Pragya Kakani, and I will be studying trends in provider profit margins on cancer drugs. @mskcancercenter.bsky.social @ascocancer.bsky.social nihcm.org/news/nihcm-a...

New study finding regional variation in adoption of PSMA PET imaging for prostate cancer. As we often see, Southeast is lagging. As this scan is prerequisite to radioligand therapy, could result in treatment disparities ascopubs.org/doi/10.1200/... @carygross.bsky.social @ascocancer.bsky.social